Eliminate drug toxicity. Expand your therapeutic index.

Equip yourself with AI models more accurate and more interpretable than traditional experiments.

Toxicity is a leading cause of clinical trial failures

Every year, unexpected toxicity denies patients many effective medicines and costs industry billions of dollars.

SOURCE GLP-1 pill for obesity discontinued due to liver toxicity April 14, 2025SOURCE Oral obesity drug dropped after seeing liver safety concern June 26, 2023SOURCE Phase II trials for Alzheimer’s terminated drug due to liver toxicity October 26, 2023SOURCE 2 deaths put gene therapy's liver safety in the spotlight once again August 12, 2022SOURCE FDA rejects would-be blockbuster over toxicity concerns August 19, 2022SOURCE Lead asset dropped over bilirubin side effects February 18, 2025
SOURCE Unfortunate and unexpected' clinical hold after liver failure in atopic dermatitis trial February 20, 2024SOURCE Stock Crashes 21% After A Surprise Side Effect Hammered Its Drug December 9, 2024SOURCE Latest victim of raised liver enzymes, shutters trial and sees shares slide December 15, 2022SOURCE FDA places warning on NK3 antagonist because it could cause liver damage September 12, 2024SOURCE Early Cancer Trial Stopped Over Liver Toxicity, Drops Out of Race May 23, 2024SOURCE BTK inhibitor again slows MS progression, but liver enzymes continue to be tricky September 20, 2024
SOURCE PTH1R agonist dropped over bilirubin side effects 4 months after going public February 18, 2025SOURCE Another Alzheimer's failure after BACE drug sparks liver safety fears June 13, 2013SOURCE Serious liver injury being observed in patients without cirrhosis taking treatment for biliary cholangitis December 12, 2024SOURCE ATR inhibitor promise for advanced solid tumors dimmed by liver toxicity April 10, 2024SOURCE In analysis of gene therapy deaths, points to underlying liver issue November 16, 2023SOURCE Stops Program Following Clinical Hold Due to Single SAE of Severe Liver Injury November 11, 2024
SOURCE Stock plummets after FDA raises safety concerns November 3, 2016SOURCE More anguish as safety signal sinks midphase kidney disease trial June 30, 2022SOURCE Strigle to escape toxicity labyrinth as safety signal sinks cancer program and share price July 13, 2023SOURCE Target candidate canned over off-target toxicity August 11, 2022SOURCE GI toxicity hits midstage GLP-1 drug as patients drop out April 27, 2018SOURCE Five Deaths in Prostate Cancer Trial Send Stock Plummeting May 10, 2024
SOURCE Out of KRAS race as toxicity sees ditched phase 1 effort July 30, 2022SOURCE Gene therapy trial halted after patient suffers serious toxicity November 12, 2019SOURCE FDA halts trial of ADC over 'significant risk of illness June 17, 2024SOURCE Halted sleep disorder med trial over 'visual disturbances' and CV effects November 29, 2023SOURCE Halted enrollment of lead trial after grade 3 side effects April 02, 2024SOURCE Paused phase 2 lung fibrosis trial on advice of safety committee February 10, 2025
SOURCE FDA Puts Clinical Hold on Drug Due to Preclinical Safety Signals April 15, 2024SOURCE Biopharma stock Crashes 21% After A Surprise Side Effect Hammered Its 'Very Safe' Drug December 9, 2024SOURCE Axed late-phase DMD drug over safety signal, FDA talks November 07, 2024SOURCE Shift in focus after FDA places hold on experimental Alzheimer’s drug January 26, 2026SOURCE FDA restricts use of drug due to liver injury risk May 27, 2021SOURCE Weight-loss meds get liver-injury warning May 27, 2010
SOURCE FDA officials worried over Ketek July 18, 2006SOURCE FDA withdraws approval of ADHD drug October 24, 2005SOURCE CGRP receptor antagonist meets Phase III migraine end points November 11, 2009SOURCE Discontinued Phase 3 Study of BTK inhibitor in Myasthenia Gravis February 7, 2023SOURCE Elevated liver enzymes force Centessa to drop a 2nd asset in 2 months August 10, 2022

Old Paradigm

40% - 55% of drugs fail because of toxicity.

  • 90% of drugs fail; toxicity is a leading cause 1 2 3

  • All drugs are tested in lab and animal experiments, but still fail clinical trials due to toxicity

  • Tens of billions of dollars are lost to late stage drug toxicity

Old Paradigm

Existing physical experiments are inaccurate and expensive.

  • Animal testing has poor predictive performance for human liver injury 4

  • Lab experiments show good specificity but lack sensitivity 5 6

  • Experiments costs thousands to millions of dollars while taking weeks to months to run

Changing Industry

Current experimental methods are becoming obsolete.

  • Congress dropped the legal requirement for animal testing7

  • Congress and the FDA have announced they are phasing out animal experiments8

  • Industry, big pharma, regulators, and academia are looking for alternative approaches

New Paradigm

Its time to accurately predict toxicity.

  • More accurate predictions of clinical outcomes

  • Affordably measure safety from the beginning of drug development

  • Save billions by reducing synthesis and assay costs and avoiding late stage failures

Assess and validate Axiom's new paradigm for yourself

Our early partners include some of the world's largest pharma companies. See what they are excited about.

FDA & Insphero

3D Spheroid

Axiom

AI experiment

AUC0.800.89
Sensitivity72%75%
Specificity90%93%

Clinical Liver Injury

Use Axiom to predict clinical liver injury with improved accuracy and lower costs.

Learn More

How it works

Axiom trains models on the world’s largest, most comprehensive dataset of primary human liver biology.

Learn More